This episode regards a United States Court of Appeals for the Federal Circuit opinion, dated October 30, 2025, concerning a patent dispute between Merck Serono S.A. and Hopewell Pharma Ventures, Inc. The case involves Merck's appeal of two consolidated inter partes reviews (IPRs) before the Patent Trial and Appeal Board (Board), which had found certain claims of two Merck patents related to an oral cladribine regimen for treating multiple sclerosis (MS) unpatentable as obvious. The primary le...
All content for Condensed IP is the property of Randy Noranbrock and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This episode regards a United States Court of Appeals for the Federal Circuit opinion, dated October 30, 2025, concerning a patent dispute between Merck Serono S.A. and Hopewell Pharma Ventures, Inc. The case involves Merck's appeal of two consolidated inter partes reviews (IPRs) before the Patent Trial and Appeal Board (Board), which had found certain claims of two Merck patents related to an oral cladribine regimen for treating multiple sclerosis (MS) unpatentable as obvious. The primary le...
Centripetal Networks v. Palo Alto Networks (Fed. Cir., October 22, 2025) 2023-2027
Condensed IP
12 minutes
1 week ago
Centripetal Networks v. Palo Alto Networks (Fed. Cir., October 22, 2025) 2023-2027
This episode concerns a decision from the United States Court of Appeals for the Federal Circuit regarding Centripetal Networks, LLC v. Palo Alto Networks, Inc. et al., decided on October 22, 2025. The core of the case involves Centripetal Networks appealing a decision by the Patent Trial and Appeal Board (PTAB) that held certain claims of their patent unpatentable as obvious. A significant issue addressed is Centripetal’s claim that the PTAB’s decision was "tainted" due to the belated recusa...
Condensed IP
This episode regards a United States Court of Appeals for the Federal Circuit opinion, dated October 30, 2025, concerning a patent dispute between Merck Serono S.A. and Hopewell Pharma Ventures, Inc. The case involves Merck's appeal of two consolidated inter partes reviews (IPRs) before the Patent Trial and Appeal Board (Board), which had found certain claims of two Merck patents related to an oral cladribine regimen for treating multiple sclerosis (MS) unpatentable as obvious. The primary le...
